Ionis Pharmaceuti…
USUSDIonis Pharmaceuticals Inc (US:IONS) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 3. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par uzņēmumu
- Tīmekļvietne
- ionis.com
- Nozare
- Health Care · Biotechnology: Pharmaceutical Preparations
- Galvenā mītne
- CARLSBAD, United States
- Izpilddirektors
- Brett P. Monia
- Darbinieki
- 1 480
- Apgrozībā esošās akcijas
- Brīvā apgrozība
- 164.82 milj.
- Tirgus kapitalizācija
- 7.42 mljrd. USD
- Iekšējās personas
- 0.61%
- Institucionālie investori
- 110.5%
- Nozare (SIC)
- Pharmaceutical Preparations
- ISIN
- US4622221004
- LEI
- 549300SI4ZGLG0BLUZ92
- Izmaksas koeficients
- 0%
- FCF
- −561 milj. USD
- Parāds
- 1.81 mljrd. USD
- Dividenžu stāžs
- —
- Peļņa, FCF un izmaksātās dividendes — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Dividendes
Dividenžu izmaksas netika atrastas (pārbaudīts 10.10.2026). Uzņēmums, visticamāk, nemaksā dividendes.
Ziņas šonedēļ
Ziņu no uzņēmuma vietnes vēl nav.
Lielākie akcionāri
| Turētājs | Daļa | Akcijas | Pārskata datums |
|---|---|---|---|
| FMR, LLC | 14.82% | 24.63 milj. | 2026-06-30 |
| Capital World Investors | 13.04% | 21.67 milj. | 2026-06-30 |
| Blackrock Inc. | 6.44% | 10.7 milj. | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 5.12% | 8.5 milj. | 2026-07-31 |
| Vanguard Portfolio Manag… | 4.73% | 7.86 milj. | 2026-06-30 |
| Growth Fund of America | 4.61% | 7.67 milj. | 2026-06-30 |
| Wellington Management Gr… | 4.6% | 7.65 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 4.34% | 7.21 milj. | 2026-06-30 |
| Two Sigma Investments, L… | 3.76% | 6.25 milj. | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 3.74% | 6.21 milj. | 2026-07-31 |
| Royal Bank of Canada | 3.72% | 6.18 milj. | 2026-06-30 |
| SmallCap World Fund Inc | 3.17% | 5.26 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3% | 4.99 milj. | 2026-06-30 |
| New Economy Fund | 2.93% | 4.87 milj. | 2026-06-30 |
| State Street Corporation | 2.61% | 4.33 milj. | 2026-06-30 |
| T. Rowe Price Investment… | 2.38% | 3.96 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 3.6 milj. | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.44% | 2.39 milj. | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.25% | 2.08 milj. | 2026-06-30 |
| T. Rowe Price Mid-Cap Gr… | 1.2% | 2 milj. | 2026-06-30 |
| MONIA BRETT P (Chief Exe… | ≈0.15% | 245 571 | 2026-06-26 |
| BERTHELSEN SPENCER R (Di… | ≈0.1% | 161 303 | 2026-07-15 |
| HOUGEN ELIZABETH L (Chie… | ≈0.05% | 82 660 | 2026-03-17 |
| SCHNEIDER EUGENE (Office… | ≈0.05% | 77 114 | 2026-06-26 |
| BIRCHLER BRIAN (Officer) | ≈0.04% | 67 500 | 2026-04-16 |
| O'NEIL PATRICK R (Genera… | ≈0.04% | 61 470 | 2026-06-26 |
| GEARY RICHARD S (Officer… | ≈0.04% | 59 657 | 2025-11-06 |
| BAROLDI JOSEPH (Officer) | — | — | 2026-06-26 |
| BENNETT C FRANK (Officer… | — | — | 2026-07-07 |
| HAYDEN MICHAEL REUBEN (D… | — | — | 2026-07-31 |